Voyager Therapeutics (NASDAQ:VYGR) Cut to “Hold” at StockNews.com

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Sunday.

VYGR has been the subject of a number of other reports. Wedbush lowered their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Wednesday, August 7th. Leerink Partners assumed coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $30.00 price target on shares of Voyager Therapeutics in a research report on Thursday, October 24th. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.43.

Voyager Therapeutics Stock Performance

VYGR stock opened at $7.13 on Friday. The firm has a fifty day moving average price of $6.60 and a 200 day moving average price of $7.54. Voyager Therapeutics has a fifty-two week low of $5.71 and a fifty-two week high of $11.72. The firm has a market cap of $388.82 million, a PE ratio of 25.46 and a beta of 0.89.

Insider Activity at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.53% of the stock is owned by insiders.

Institutional Investors Weigh In On Voyager Therapeutics

Large investors have recently bought and sold shares of the company. Great Point Partners LLC acquired a new position in Voyager Therapeutics in the second quarter valued at approximately $12,668,000. Farallon Capital Management LLC lifted its holdings in Voyager Therapeutics by 77.4% in the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock valued at $21,339,000 after acquiring an additional 1,000,000 shares during the period. Vanguard Group Inc. lifted its holdings in Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after acquiring an additional 702,030 shares during the period. Armistice Capital LLC lifted its holdings in Voyager Therapeutics by 11.3% in the second quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after acquiring an additional 528,000 shares during the period. Finally, American Century Companies Inc. lifted its holdings in Voyager Therapeutics by 32.4% in the second quarter. American Century Companies Inc. now owns 1,019,332 shares of the company’s stock valued at $8,063,000 after acquiring an additional 249,659 shares during the period. Hedge funds and other institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.